Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

125,584 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Adjuvant Apatinib in Nasopharyngeal Carcinoma With Residual Epstein-Barr Virus DNA After Radiation Therapy: A Biomarker-Driven, Phase 2 Trial.
Liu X, Guo L, Xie FY, Hu WH, Chen MY, He QM, Xu ZM, Zhang CQ, Peng YL, Tang LL, Mao YP, Sun R, Li JB, Argiris A, Hui EP, Sun Y, Ma J. Liu X, et al. Int J Radiat Oncol Biol Phys. 2022 Aug 1;113(5):1063-1071. doi: 10.1016/j.ijrobp.2022.04.049. Epub 2022 May 9. Int J Radiat Oncol Biol Phys. 2022. PMID: 35550406 Clinical Trial.
Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial.
Chen YP, Liu X, Zhou Q, Yang KY, Jin F, Zhu XD, Shi M, Hu GQ, Hu WH, Sun Y, Wu HF, Wu H, Lin Q, Wang H, Tian Y, Zhang N, Wang XC, Shen LF, Liu ZZ, Huang J, Luo XL, Li L, Zang J, Mei Q, Zheng BM, Yue D, Xu J, Wu SG, Shi YX, Mao YP, Chen L, Li WF, Zhou GQ, Sun R, Guo R, Zhang Y, Xu C, Lv JW, Guo Y, Feng HX, Tang LL, Xie FY, Sun Y, Ma J. Chen YP, et al. Among authors: liu zz, liu x. Lancet. 2021 Jul 24;398(10297):303-313. doi: 10.1016/S0140-6736(21)01123-5. Epub 2021 Jun 7. Lancet. 2021. PMID: 34111416 Clinical Trial.
Effect of Radiotherapy Alone vs Radiotherapy With Concurrent Chemoradiotherapy on Survival Without Disease Relapse in Patients With Low-risk Nasopharyngeal Carcinoma: A Randomized Clinical Trial.
Tang LL, Guo R, Zhang N, Deng B, Chen L, Cheng ZB, Huang J, Hu WH, Huang SH, Luo WJ, Liang JH, Zheng YM, Zhang F, Mao YP, Li WF, Zhou GQ, Liu X, Chen YP, Xu C, Lin L, Liu Q, Du XJ, Zhang Y, Sun Y, Ma J. Tang LL, et al. Among authors: liu x, liu q. JAMA. 2022 Aug 23;328(8):728-736. doi: 10.1001/jama.2022.13997. JAMA. 2022. PMID: 35997729 Free PMC article. Clinical Trial.
Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma.
Zhang Y, Chen L, Hu GQ, Zhang N, Zhu XD, Yang KY, Jin F, Shi M, Chen YP, Hu WH, Cheng ZB, Wang SY, Tian Y, Wang XC, Sun Y, Li JG, Li WF, Li YH, Tang LL, Mao YP, Zhou GQ, Sun R, Liu X, Guo R, Long GX, Liang SQ, Li L, Huang J, Long JH, Zang J, Liu QD, Zou L, Su QF, Zheng BM, Xiao Y, Guo Y, Han F, Mo HY, Lv JW, Du XJ, Xu C, Liu N, Li YQ, Chua MLK, Xie FY, Sun Y, Ma J. Zhang Y, et al. Among authors: liu x, liu qd, liu n. N Engl J Med. 2019 Sep 19;381(12):1124-1135. doi: 10.1056/NEJMoa1905287. Epub 2019 May 31. N Engl J Med. 2019. PMID: 31150573 Clinical Trial.
Combining tumor response and personalized risk assessment: Potential for adaptation of concurrent chemotherapy in locoregionally advanced nasopharyngeal carcinoma in the intensity-modulated radiotherapy era.
Luo WJ, Zou WQ, Liang SB, Chen L, Zhou GQ, Peng H, Li WF, Liu X, Sun Y, Lin AH, Ma J, Mao YP. Luo WJ, et al. Among authors: liu x. Radiother Oncol. 2021 Feb;155:56-64. doi: 10.1016/j.radonc.2020.10.005. Epub 2020 Oct 8. Radiother Oncol. 2021. PMID: 33039423
A Gene-Expression Predictor for Efficacy of Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma.
Lei Y, Li YQ, Jiang W, Hong XH, Ge WX, Zhang Y, Hu WH, Wang YQ, Liang YL, Li JY, Cho WCS, Yun JP, Zeng J, Chen JW, Liu LZ, Li L, Chen L, Xie FY, Li WF, Mao YP, Liu X, Chen YP, Tang LL, Sun Y, Liu N, Ma J. Lei Y, et al. Among authors: liu x, liu n, liu lz. J Natl Cancer Inst. 2021 Apr 6;113(4):471-480. doi: 10.1093/jnci/djaa100. J Natl Cancer Inst. 2021. PMID: 33094348 Free PMC article.
Unraveling tumour microenvironment heterogeneity in nasopharyngeal carcinoma identifies biologically distinct immune subtypes predicting prognosis and immunotherapy responses.
Chen YP, Lv JW, Mao YP, Li XM, Li JY, Wang YQ, Xu C, Li YQ, He QM, Yang XJ, Lei Y, Shen JY, Tang LL, Chen L, Zhou GQ, Li WF, Du XJ, Guo R, Liu X, Zhang Y, Zeng J, Yun JP, Sun Y, Liu N, Ma J. Chen YP, et al. Among authors: liu x, liu n. Mol Cancer. 2021 Jan 11;20(1):14. doi: 10.1186/s12943-020-01292-5. Mol Cancer. 2021. PMID: 33430876 Free PMC article.
125,584 results
You have reached the last available page of results. Please see the User Guide for more information.